Drug Resistance in Leishmaniasis

The treatment options of leishmaniasis are limited and far from satisfactory. For more than 60 years, treatment of leishmaniasis has centered around pentavalent antimonials (Sbv). Widespread misuse has led to the emergence of Sbv resistance in the hyperendemic areas of North Bihar. Other antileishmanials could also face the same fate, especially in the anthroponotic cycle. The HIV/ visceral leishmaniasis (VL) coinfected patients are another potential source for the emergence of drug resistance. At present no molecular markers of resistance are available and the only reliable method for monitoring resistance of isolates is the technically demanding in vitro amastigote-macrophage model. As the armametrium of drugs for leishmaniasis is limited, it is important that effective monitoring of drug use and response should be done to prevent the spread of resistance. Regimens of simultaneous or sequential combinations should be seriously considered to limit the emergence of resistance.

• Publication year

  2010

• Venue

  Journal of Global Infectious Diseases

• Publication date

  2010-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4103/0974-777X.62887PMID 20606973PMCID 2889657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paromomycin: uptake and resistance in Leishmania donovani.

  2009cited by this paper
• Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India

  2009cited by this paper
• New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.

  2008cited by this paper
• Injectable paromomycin for Visceral leishmaniasis in India.

  2007cited by this paper
• Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.

  2006cited by this paper
• Drug Resistance in Leishmaniasis

  2006cited by this paper
• Phospholipid Translocation and Miltefosine Potency Require Both L. donovani Miltefosine Transporter and the New Protein LdRos3 in Leishmania Parasites*

  2006cited by this paper
• Molecular mechanisms of drug resistance

  2005cited by this paper
• A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.

  2005cited by this paper
• Role of the ABC Transporter MRPA (PGPA) in Antimony Resistance in Leishmania infantum Axenic and Intracellular Amastigotes

  2005cited by this paper
• A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.

  2005cited by this paper
• Availability of miltefosine for the treatment of kala-azar in India.

  2005cited by this paper
• The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.

  2005cited by this paper
• Genital manifestations of tropical diseases

  2004cited by this paper
• Leishmania major LmACR2 Is a Pentavalent Antimony Reductase That Confers Sensitivity to the Drug Pentostam*

  2004cited by this paper
• Trypanothione S-Transferase Activity in a Trypanosomatid Ribosomal Elongation Factor 1B*

  2004cited by this paper
• Drug Uptake and Modulation of Drug Resistance in Leishmania by an Aquaglyceroporin*

  2004cited by this paper
• Pharmacokinetics of Antimony in Patients Treated with Sodium Stibogluconate for Cutaneous Leishmaniasis

  2004cited by this paper
• Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing

  2004cited by this paper
• Miltefosine Induces Apoptosis-Like Death in Leishmania donovani Promastigotes

  2004cited by this paper
• A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis.

  2004cited by this paper
• Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1.

  2004cited by this paper
• Cloning of S-Adenosyl-l-Methionine:C-24-Δ-Sterol-Methyltransferase (ERG6) from Leishmania donovani and Characterization of mRNAs in Wild-Type and Amphotericin B-Resistant Promastigotes

  2004cited by this paper
• Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.

  2004cited by this paper
• Evaluation of a urinary antigen‐based latex agglutination test in the diagnosis of kala‐azar in eastern Nepal

  2004cited by this paper
• A trypanothione-dependent glyoxalase I with a prokaryotic ancestry in Leishmania major.

  2004cited by this paper
• Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania donovani*

  2004cited by this paper
• Possible Mechanism of Miltefosine-Mediated Death of Leishmania donovani

  2004cited by this paper
• Miltefosine for new world cutaneous leishmaniasis.

  2004influential reference
• [Childhood Mediterranean visceral leishmaniasis].

  2003cited by this paper
• Functional Cloning of the Miltefosine Transporter

  2003cited by this paper
• Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

  2003cited by this paper
• Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

  2003cited by this paper
• Leishmaniasis: new approaches to disease control

  2003cited by this paper
• The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV

  2003cited by this paper
• Novel mechanism of drug resistance in kala azar field isolates.

  2003cited by this paper
• Cytochrome C-mediated apoptosis.

  2003cited by this paper
• Visceral Leishmaniasis Treatment, Italy

  2003cited by this paper
• [A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis].

  2003cited by this paper
• Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major.

  2003cited by this paper
• Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione

  2003cited by this paper
• Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa.

  2003cited by this paper
• Rapid reduction of pentavalent antimony by trypanothione: potential relevance to antimonial activation.

  2003cited by this paper
• Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.

  2003cited by this paper
• Antimony Uptake Systems in the Protozoan Parasite Leishmania and Accumulation Differences in Antimony-Resistant Parasites

  2003cited by this paper
• Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.

  2003cited by this paper
• An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans.

  2003cited by this paper
• Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.

  2003cited by this paper
• Leishmania donovani Resistance to Miltefosine Involves a Defective Inward Translocation of the Drug

  2003cited by this paper
• Antimonial-induced Increase in Intracellular Ca2+ through Non-selective Cation Channels in the Host and the Parasite Is Responsible for Apoptosis of Intracellular Leishmania donovani Amastigotes*

  2003cited by this paper
• Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran.

  2003cited by this paper
• Leishmania/HIV co-infections: epidemiology in Europe

  2003cited by this paper
• Thiol-induced reduction of antimony(V) into antimony(III): A comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione

  2003cited by this paper
• Pentamidine uptake and resistance in pathogenic protozoa: past, present and future.

  2003cited by this paper
• Mechanism of impairment of cytochrome P450-dependent metabolism in hamster liver during leishmaniasis.

  2003cited by this paper
• The de novo selection of drug–resistant malaria parasites

  2003cited by this paper
• The In Vivo Susceptibility of Leishmania donovani to Sodium Stibogluconate Is Drug Specific and Can Be Reversed by Inhibiting Glutathione Biosynthesis

  2003cited by this paper
• Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation.

  2003cited by this paper
• HIV and the transmission of Leishmania

  2003cited by this paper
• Disruption of Ergosterol Biosynthesis Confers Resistance to Amphotericin B in Candida lusitaniae

  2003cited by this paper
• Visceral leishmaniasis : current status of control, diagnosis, and treatment, and a proposed research and development agenda

  2002cited by this paper
• Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).

  2002cited by this paper
• Resistance to Pentamidine in Leishmania mexicana Involves Exclusion of the Drug from the Mitochondrion

  2002cited by this paper
• Oral miltefosine for Indian visceral leishmaniasis.

  2002cited by this paper
• Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.

  2002cited by this paper
• Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study.

  2002cited by this paper
• Amphotericin B: spectrum and resistance.

  2002cited by this paper
• Leishmania in discarded syringes from intravenous drug users.

  2002cited by this paper
• Chemotherapy of leishmaniasis.

  2002cited by this paper
• Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

  2002cited by this paper
• Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.

  2002cited by this paper
• Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents.

  2002cited by this paper
• Strain typing in Leishmania donovani by using sequence-confirmed amplified region analysis.

  2002cited by this paper
• Drug resistance in Indian visceral leishmaniasis

  2001cited by this paper
• Glutathione-Induced Conversion of Pentavalent Antimony to Trivalent Antimony in Meglumine Antimoniate

  2001cited by this paper
• A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis.

  2001cited by this paper
• The Leishmania ATP-binding Cassette Protein PGPA Is an Intracellular Metal-Thiol Transporter ATPase*

  2001cited by this paper
• Activities of Hexadecylphosphocholine (Miltefosine), AmBisome, and Sodium Stibogluconate (Pentostam) againstLeishmania donovani in Immunodeficient scidMice

  2001cited by this paper
• Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana.

  2001cited by this paper
• Ovothiol and trypanothione as antioxidants in trypanosomatids.

  2001cited by this paper
• A policy for leishmaniasis with respect to the prevention and control of drug resistance

  2001influential reference
• Gene amplification in amphotericin B-resistant Leishmania tarentolae.

  2001cited by this paper
• Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.

  2001cited by this paper
• Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.

  2001cited by this paper
• Antimonial-Mediated DNA Fragmentation inLeishmania infantum Amastigotes

  2001cited by this paper
• Resistance to treatment in Kala-azar: speciation of isolates from northeast India.

  2001cited by this paper
• The increase in risk factors for leishmaniasis worldwide.

  2001cited by this paper
• Is reversal of chloroquine resistance ready for the clinic?

  2001cited by this paper
• Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania donovani *

  2001cited by this paper
• Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.

  2001cited by this paper
• A revised classification for Leishmania and Endotrypanum.

  2000cited by this paper
• Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria.

  2000cited by this paper
• Interaction of antimony tartrate with the tripeptide glutathione implication for its mode of action.

  2000cited by this paper
• Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

  2000cited by this paper
• Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance.

  2000cited by this paper
• A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

  2000cited by this paper
• Short-course of oral miltefosine for treatment of visceral leishmaniasis.

  2000cited by this paper
• Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

  2000cited by this paper
• What is antibiotic resistance and how can we measure it?

  2000cited by this paper
• Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

  1999cited by this paper

• Sodium perborate tetrahydrate triggers mitochondrial dysfunction in Leishmania infantum parasites and enhances antileishmanial activity in macrophages.

  2026cites this paper
• Post-kala-azar dermal leishmaniasis: insights into underlying pathogenic mechanisms and genetic landscape

  2026cites this paper
• Insights into drug resistance in Leishmania: Mechanisms, therapeutics, and clinical case studies

  2026cites this paper
• Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis

  2026cites this paper
• Comparação entre antimoniato de meglumina e miltefosina no tratamento da leishmaniose cutânea do Novo Mundo: revisão sistemática e metanálise

  2026cites this paper
• Exploring the potential of coumarin-indole hybrid scaffold as promising pharmacological agents: a review

  2025cites this paper
• Combating Drug‐Resistant Protozoal Infections: A Review of Emerging Therapeutics

  2025cites this paper
• Genetic Manipulation Tools in Leishmania: From CRISPR/Cas9 to Vaccine Strategies for Disease Control

  2025cites this paper
• Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform

  2025cites this paper
• Evaluation of the Anti-Leishmanial Activity of the Hydroalcoholic Extract of Green Algae (Spirogyra): Investigation of Weight Indicators (Lesion Size and Organ Weights) in BALB/c Mice

  2025cites this paper
• The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

  2025cites this paper
• Advancing Insights Into Visceral Leishmaniasis: Challenges, Innovations, and Future Directions in Global Disease Management

  2025cites this paper
• Lack of relationship on in vitro susceptibility of Leishmania (Viannia) braziliensis promastigotes and Leishmania RNA virus 1 to the trivalent antimonial

  2025cites this paper
• NAMS task force report on vector borne diseases

  2025cites this paper
• N-Myristoyltransferase Inhibition in Parasitic Pathogens: Insights from Computer-Aided Drug Design

  2025cites this paper
• Dual role of ionic liquids in quinoline scaffolds syntheses: a green and sustainable perspective

  2025cites this paper
• Fluorescence Spectroscopy Reveals Resveratrol Binding to a Hydrophobic Pocket in Leishmania amazonensis Sir2-Related Protein 1 (LaSir2RP1)

  2025cites this paper
• Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study.

  2025cites this paper
• A review on quinolines: New green synthetic methods and bioactive potential.

  2025cites this paper
• Effect of Lupeol on Inducing the Nitric Oxide Production in Macrophages Infected with Leishmania Donovani

  2025cites this paper
• Cutaneous and Mucocutaneous Leishmaniasis: Perspectives on Immunity, Virulence, and Treatment

  2025cites this paper
• Biogenically Synthesized Nanoparticles as Emerging Therapeutics for Leishmaniasis: A Review of Recent Advances and Potential Promises

  2025cites this paper
• Identification of potent inhibitors of Leishmania donovani and Leishmania infantum chagasi, the causative agents of Old and New World visceral leishmaniasis

  2025cites this paper
• Relapse Kala-azar: A potential threat to sustaining public health elimination in Bangladesh and ways to overcome it

  2025cites this paper
• Cutaneous Leishmaniasis in the Context of Global Travel, Migration, Refugee Populations, and Humanitarian Crises

  2025cites this paper
• Synthesis, evaluation of the biological activity against Trypanosoma cruzi and Leishmania donovani. Preliminary in silico ADMET studies of 5-nitroimidazole derivatives

  2025cites this paper
• Recent advances in the genetic engineering of the Leishmania parasite and anti-cancer properties

  2025cites this paper
• Antiprotozoal Agents - Integration of Drug Discovery, Medicinal Chemistry, and Advanced Computational Approaches: An In-depth review

  2025cites this paper
• Molecular docking of Berberis asiatica-derived compounds targeting DDX3 DEAD BOX RNA helicase of Leishmania donovani

  2025cites this paper
• Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment

  2025cites this paper
• Advances in Drug Delivery Systems for Treatment of Leishmaniases: A review.

  2025cites this paper
• Skimmin as lead inhibitor of Leishmania donovani’s O-acetyltransferase: a computational study

  2024cites this paper
• Understanding American tegumentary leishmaniasis in urban Montes Claros, Brazil: insights from clinical, immunological and therapeutic investigations

  2024cites this paper
• Harnessing the Power of Curcumin: Evaluating Its Efficacy as an Antileishmanial Agent in the Fight Against Leishmaniasis

  2024cites this paper
• Phylogenetic analysis and antimony resistance of Leishmania major isolated from humans and rodents.

  2024cites this paper
• Natural products with antiparasitic activity: Bioactive extracts from Kenyan flora against leishmaniasis

  2024cites this paper
• In Vitro Antileishmanial and Immune Modulation of Trigonelline Against Leishmania major

  2024cites this paper
• The expression of the miR-193, miR-122 and miR-155 profiling and evaluation the serum lipid in antimony-susceptible and resistance patients with cutaneous leishmaniasis

  2024cites this paper
• In vitro and in vivo anti-parasitic activity of curcumin nanoemulsion on Leishmania major (MRHO/IR/75/ER)

  2024cites this paper
• Identification of novel inhibitors from Rubus ellipticus as anti-leishmanial agents targeting DDX3-DEAD box RNA helicase of Leishmania donovani

  2024cites this paper
• Distribution and ecological aspects of sand fly species from Kousseri, an endemic focus of visceral leishmaniasis in Northern Cameroon

  2024cites this paper
• Epidemiological features of leishmaniasis and implications for public health in the eastern region of Morocco

  2024cites this paper
• Identification of Leishmania donovani PEX5-PTS1 Interaction Inhibitors through Fluorescence Polarization-Based High-Throughput Screening

  2024cites this paper
• Synthesis of Hybrid Molecules with Imidazole-1,3,4-thiadiazole Core and Evaluation of Biological Activity on Trypanosoma cruzi and Leishmania donovani

  2024cites this paper
• Casiopeina III-ia: A Copper Compound with Potential Use for Treatment of Infections Caused by Leishmania mexicana

  2024cites this paper
• Comparing the efficacy of fluconazole and cryotherapy Versus cryotherapy alone on treating cutaneous leishmaniasis: a triple-blind randomized clinical trial

  2024cites this paper
• Current and emerging therapies for the treatment of leishmaniasis

  2024cites this paper
• Aurantoside L, a New Tetramic Acid Glycoside with Anti-Leishmanial Activity Isolated from the Marine Sponge Siliquariaspongia japonica

  2024cites this paper
• GRASP negatively regulates the secretion of the virulence factor gp63 in Leishmania

  2024cites this paper
• Sojourn of Nitrogenous Heterocycles as Promising Antileishmanial Agents: Medicinal Perspectives and Structure–Activity Relationship Studies

  2024cites this paper
• Simultaneous Application of Thymoquinone and Hydroxychloroquine Suppresses Autophagy and Disrupts the Autophagosomal Trench Engulfed Leishmania major

  2024cites this paper
• Nicotinamide mitigates visceral leishmaniasis by regulating inflammatory response and enhancing lipid metabolism

  2024cites this paper
• Exploring the Potential of Malvidin and Echiodinin as Probable Antileishmanial Agents Through In Silico Analysis And In Vitro Efficacy

  2024cites this paper
• Universal PCR assays for the differential detection of all Old World species

  2023cites this paper
• Histological findings associated with treatment response in cutaneous leishmaniasis: a clinicopathological correlation study

  2023cites this paper
• Serum Levels of Vitamins and Trace Elements in Patients with Visceral Leishmaniasis: a Systematic Review and Meta-analysis

  2023cites this paper
• Cutaneous Leishmaniasis: Physiopathology, Molecular Diagnostic, and Therapeutic Approaches

  2023cites this paper
• Synthetic product-based approach toward potential antileishmanial drug development.

  2023cites this paper
• In vitro drug susceptibility using a parasite-rescue and transformation assay of Leishmania (Mundinia) martiniquensis and Leishmania (Mundinia) orientalis amastigotes against antileishmanial drugs.

  2023cites this paper
• RES-Seq—a barcoded library of drug-resistant Leishmania donovani allowing rapid assessment of cross-resistance and relative fitness

  2023cites this paper
• Managing visceral leishmaniasis

  2023cites this paper
• Organic and Inorganic Light Emitting Diodes for Photodynamic Therapy of Cutaneous Leishmaniasis

  2023cites this paper
• Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

  2023cites this paper
• Synthesis, Antileishmanial Activity and Molecular Docking Study of a Series of Dihydropyridine Derivatives

  2023cites this paper
• Leishmania major-induced alteration of host cellular and systemic copper homeostasis drives the fate of infection

  2023cites this paper
• A molecular signature for IL-10–producing Th1 cells in protozoan parasitic diseases

  2023cites this paper
• Green SPIONs as a novel highly selective treatment for leishmaniasis: an in vitro study against Leishmania amazonensis intracellular amastigotes

  2023cites this paper
• Recent Advances in Chemotherapeutics for Leishmaniasis: Importance of the Cellular Biochemistry of the Parasite and Its Molecular Interaction with the Host

  2023cites this paper
• A case of canine visceral leishmaniasis of unknown origin in Curitiba (state of Paraná, Brazil) treated successfully with miltefosine

  2023cites this paper
• Translational reprogramming as a driver of antimony-drug resistance in Leishmania

  2023cites this paper
• Pharmacophore-guided drug design using LdNMT as a model drug target for leishmaniasis

  2023cites this paper
• Synthesis and physicochemical characterization of Zn-Al layered double hydroxides (LDHs) as a delivery system for amphotericin B: In vitro and in silico antileishmanial study.

  2023cites this paper
• Assessment of Nanoencapsulated Syzygium Aromaticum Essential Oil in Chitosan-Alginate Nanocareer as a New Antileishmanial and Antimicrobial System Approach

  2023cites this paper
• Title : MAPK / ERK Activation in Macrophages Promotes Leishmania 1 Internalization and Pathogenesis 2 3 Running title : ERK 1 / 2 facilitates Leishmania internalization

  2023cites this paper
• Synthetic Cinnamides and Cinnamates: Antimicrobial Activity, Mechanism of Action, and In Silico Study

  2023cites this paper
• Nanomaterials as a Potential Target for Infectious Parasitic Agents.

  2023cites this paper
• CUTANEOUS LEISHMANIASIS AND THE BRAZILIAN POPULATION IN THE LAST DECADES

  2023cites this paper
• Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected with Leishmania infantum

  2023cites this paper
• Novel Pyrido[2',1':2,3]imidazo[4,5-c]quinoline Derivative Selectively Poisons Leishmania donovani Bisubunit Topoisomerase 1 to Inhibit the Antimony-Resistant Leishmania Infection in Vivo.

  2023cites this paper
• An anti‐leishmanial compound 4′,7‐dihydroxyflavone elicits ROS‐mediated apoptosis‐like death in Leishmania parasite

  2023cites this paper
• Ethanolaminephosphate cytidyltransferase is essential for survival, lipid homeostasis and stress tolerance in Leishmania major

  2023cites this paper
• Prosopis juliflora (Sw.) DC.induces apoptotic-like programmed cell death in Leishmania donovani via over production of oxidative stress, mitochondrial dysfunction and ATP depletion

  2023cites this paper
• Promising natural products for the treatment of cutaneous leishmaniasis: A review of in vitro and in vivo studies.

  2023cites this paper
• Current Status on 1,4-Dihydropyridine Derivatives against Human Pathogenic Parasites.

  2022cites this paper
• Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties

  2022cites this paper
• In vitro and in vivo therapeutic antileishmanial potential of ellagic acid against Leishmania donovani in murine model

  2022cites this paper
• Systemic Drugs Used to Treat American Tegumentary Leishmaniasis

  2022cites this paper
• Evaluation of the Efficacy of Amphotericin B and Terbinafine Microemulsions and Their Combination on Cutaneous Leishmaniasis and Comparison with the Conventional Drug Form in BALB/c Mice

  2022cites this paper
• Effectiveness of an O-Alkyl Hydroxamate in Dogs with Naturally Acquired Canine Leishmaniosis: An Exploratory Clinical Trial

  2022cites this paper
• Antileishmanial Activities of (Z)-2-(Nitroimidazolylmethylene)-3(2H)-Benzofuranones: Synthesis, In Vitro Assessment, and Bioactivation by NTR 1 and 2

  2022influential citation
• Synthesis, antimalarial, antileishmanial evaluation, and molecular docking study of some 3-aryl-2-styryl substituted-4(3H)-quinazolinone derivatives

  2022cites this paper
• Journal Pre-proof and in animal infections where salvage of host sphingomyelin predominates

  2022cites this paper
• Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments

  2022cites this paper
• Evaluating complete surface-associated and secretory proteome of Leishmania donovani for discovering novel vaccines and diagnostic targets

  2022cites this paper
• Liposomal drug delivery systems for the treatment of leishmaniasis

  2022cites this paper
• Knockout of Tyrosine Aminotransferase Gene by Homologous Recombination Arrests Growth and Disrupts Redox Homeostasis in Leishmania Parasite

  2022cites this paper
• Monomethylsulochrin isolated from biomass extract of Aspergillus sp. against Leishmania amazonensis: In vitro biological evaluation and molecular docking

  2022cites this paper
• Strong effects of parasite genotype on drug susceptibility in the Indian subcontinent

  2022cites this paper
• Amino acid containing amphiphilic hydrogelators with antibacterial and antiparasitic activities.

  2022cites this paper
• In vitro/in vivo assessment and cellular mechanisms of Astragalus spinosus Extract againstLeishmania major

  2022cites this paper